12,357 Shares in Omnicell, Inc. (NASDAQ:OMCL) Bought by Shaker Investments LLC OH

Shaker Investments LLC OH bought a new position in shares of Omnicell, Inc. (NASDAQ:OMCL) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 12,357 shares of the company’s stock, valued at approximately $550,000.

Other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC boosted its position in Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after buying an additional 553 shares in the last quarter. KBC Group NV boosted its stake in shares of Omnicell by 60.8% during the fourth quarter. KBC Group NV now owns 2,057 shares of the company’s stock valued at $92,000 after purchasing an additional 778 shares in the last quarter. 1620 Investment Advisors Inc. grew its holdings in shares of Omnicell by 230.1% during the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after purchasing an additional 1,542 shares during the last quarter. Summit Global Investments acquired a new position in shares of Omnicell in the third quarter valued at approximately $221,000. Finally, QRG Capital Management Inc. bought a new position in Omnicell in the 3rd quarter valued at approximately $231,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Wells Fargo & Company reduced their price target on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Barclays raised their price objective on Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Benchmark reiterated a “buy” rating and issued a $62.00 target price on shares of Omnicell in a report on Tuesday, February 4th. Finally, Craig Hallum raised their price target on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Omnicell presently has a consensus rating of “Hold” and a consensus price target of $52.33.

Omnicell Stock Performance

Shares of OMCL opened at $42.40 on Tuesday. Omnicell, Inc. has a one year low of $25.12 and a one year high of $55.74. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 0.95. The stock has a 50-day moving average of $44.21 and a 200-day moving average of $43.48. The company has a market cap of $1.96 billion, a PE ratio of 157.04, a P/E/G ratio of 26.98 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, equities research analysts predict that Omnicell, Inc. will post 1.04 EPS for the current fiscal year.

Insider Activity

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the sale, the director now directly owns 58,427 shares of the company’s stock, valued at $2,763,597.10. This trade represents a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 2.64% of the company’s stock.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.